Brief: Biogen, Forward Pharma to enter into settlement and license agreement

Forward Pharma A/S

17/01/2017 12:30

Jan 17 (Reuters) - Biogen Inc  BIIB.O  
    * Biogen and Forward Pharma agree to enter into settlement 
and license agreement 
    * Biogen - Biogen to pay $1.25b in exchange for license 
agreement to Forward Pharma intellectual property 
    * Biogen - future payment of royalties subject to resolution 
of ongoing patent procedures in US and EU 
    * License agreement will provide Biogen an irrevocable 
license to all intellectual property owned by Forward Pharma 
    * Biogen - settlement and license agreement does not resolve 
issues pending in ongoing interference proceeding in U.S. or 
opposition proceeding in EU 
    * Biogen - non-refundable cash payment of $1.25 billion will 
not affect Biogen's 2016 non-gaap financial results 
 
Source text for Eikon:  ID:nBwbcVCJfa  
Further company coverage:  BIIB.O  
 
 ((Bangalore.newsroom@thomsonreuters.com;))